chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Swelling, Vertigo
Clinical narrative: Dizziness; Weakness; Chills; Fatigue; Swelling of the neck; Vertigo; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN0153) via an unspecified route of administration in the left arm on 07Apr2021 at 09:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included fish oil (OMEGA 3) and cyanocobalamin (B 12), both taken for unspecified indications from unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021, the patient experienced dizziness, weakness, chills, fatigue and swelling of the neck. On an unknown date in Apr2021, two weeks later, the patient experienced vertigo; fatigue and vertigo were present at the time of this report. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown if any therapeutic measures were taken as a result of the events. On 19Apr2021, the patient underwent COVID-19 test (nasal swab) and the result was negative. The clinical outcome of the events dizziness, weakness, chills and swelling of the neck were resolved with lasting effects on an unknown date in Apr2021, while fatigue and vertigo were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation
Clinical narrative: Arm that received shot, and face, are burning as if there's a bad sunburn.; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 15:45 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and mild hypothyroidism. The patient had known allergies to latex, wheat, corn, soy, rice and aspirin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021 at 17:15, the patient experienced arm that received shot, and face, were burning as if there's a bad sunburn. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events arm that received shot, and face, were burning as if there's a bad sunburn was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Developed first time shingles less than a week after second dose; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 27Mar2021 at 12:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included morbidly obese, tachycardia, sleep apnea, eosinophilic esophagitis (EoE), chronic migraine, depression, anxiety, seafood allergy (smoked salmon) and allergy to nuts (some nuts). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included duloxetine hydrochloride (CYMBALTA), bupropion hydrochloride (WELLBUTRIN), propranolol (MANUFACTURER UNKNOWN) and pantoprazole (MANUFACTURER UNKNOWN) for unknown indication for unspecified date. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 04Mar2021 at 13:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. On 02Apr2021 at 15:00, the patient developed first time shingles less than a week after second dose. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of shingles which included treatment with antiviral medication and prednisone. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event shingles less than a week after second dose was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Paraesthesia
Clinical narrative: Dizziness; face tingling; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 19Apr2021 at 14:45 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received unspecified medications within two weeks of vaccination. On 19Apr2021 at 15:00, the patient experienced dizziness and face tingling. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness and face tingling was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Conjunctivitis, Fatigue, Headache
Clinical narrative: Grade 2 fatigue; Grade 2 fever with a temperature of 102.5; Grade 2 myalgia; Grade 1 chills; Grade 1 conjunctivitis; Grade 1 edema limbs; Grade 1 injection site reaction; Grade 1 headache; This is a spontaneous report from a contactable physician, the patient. A 42-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the right arm on 20Apr2021 at 09:45 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Other medical history was reported as none. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 30Mar2021 at 09:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 at 20:00, approximately 10 hours after receiving the second dose of the Pfizer covid vaccine, the patient developed the following symptoms: Grade 2 fatigue, Grade 2 fever with a temperature of 102.5, Grade 2 myalgia, Grade 1 chills, Grade 1 conjunctivitis, Grade 1 edema limbs, Grade 1 injection site reaction and Grade 1 headache. On 20Apr2021 at 20:00, the patient underwent body temperature and the result was 102.5 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with Tylenol. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events Grade 2 fever with a temperature of 102.5 and Grade 1 chills was recovered on an unknown date in Apr2021. The clinical outcome of the events Grade 2 fatigue, Grade 2 myalgia, Grade 1 conjunctivitis, Grade 1 edema limbs, Grade 1 injection site reaction and Grade 1 headache was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Oedema peripheral, Pyrexia, Vaccination site reaction
Clinical narrative: Grade 2 fatigue; Grade 2 fever with a temperature of 102.5; Grade 2 myalgia; Grade 1 chills; Grade 1 conjunctivitis; Grade 1 edema limbs; Grade 1 injection site reaction; Grade 1 headache; This is a spontaneous report from a contactable physician, the patient. A 42-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the right arm on 20Apr2021 at 09:45 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Other medical history was reported as none. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 30Mar2021 at 09:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 at 20:00, approximately 10 hours after receiving the second dose of the Pfizer covid vaccine, the patient developed the following symptoms: Grade 2 fatigue, Grade 2 fever with a temperature of 102.5, Grade 2 myalgia, Grade 1 chills, Grade 1 conjunctivitis, Grade 1 edema limbs, Grade 1 injection site reaction and Grade 1 headache. On 20Apr2021 at 20:00, the patient underwent body temperature and the result was 102.5 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with Tylenol. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events Grade 2 fever with a temperature of 102.5 and Grade 1 chills was recovered on an unknown date in Apr2021. The clinical outcome of the events Grade 2 fatigue, Grade 2 myalgia, Grade 1 conjunctivitis, Grade 1 edema limbs, Grade 1 injection site reaction and Grade 1 headache was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia
Clinical narrative: Loss of taste; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 11:30 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication received within two weeks of vaccination was not reported. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (age at vaccination unknown) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021, the patient experienced loss of taste. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event loss of taste was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus has gone from very quiet and manageable to very loud.; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 06Apr2021 at 00:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included "BP and Thyroid meds" (blood pressure and thyroid medications). The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified BP (blood pressure) and thyroid meds (medications) taken from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 11Apr2021 at 00:00, the patient experienced tinnitus which had gone from very quiet and manageable to very loud. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus had gone from very quiet and manageable to very loud was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen Lymph nodes under left arm; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 17Apr2021 at 10:30 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. The patient medical history included asthma. The patient previously received acetylsalicylic acid (ASPRIN) on an unknown date for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 27Mar2021 at 11:00 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. On 18Apr2021, the patient experienced swollen lymph nodes under left arm. Therapeutic measures were not taken as a result of the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen Lymph nodes under left arm was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pyrexia
Clinical narrative: Fever; Chills; Whole body aches; Headaches; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 09:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19.  Concomitant medications included cetirizine hydrochloride (ZYRTEC), lamotrigine (MANUFACTURER UNKNOWN) and vortioxetine hydrobromide (TRINTELLIX); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 09:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 23:00, the patient experienced fever, chills, whole body aches and headaches which were most intense from 23:00-5:00 and symptoms continued through following day decreasing slightly. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, whole body aches and headaches was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Very bad random itching; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0150) via an unspecified route of administration in the left arm on 05Apr2021 at 12:00 (at the age of 65-year-old) as a single dose for COVID-19 immunisation. Medical history included osteoporosis, allergy to penicillin and sulfonamide. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included vitamin d nos (VITAMIN D) and calcium supplement (MANUFACTURER UNKNOWN) both for an unknown indications on unknown dates and unknown if ongoing. The patient previously received denosumab (PROLIA) for osteoporosis, last shot was in Nov2020. Also the patient previously received amoxicillin (MANUFACTURER UNKNOWN), mefenamic acid (ADVIL), ibuprofen (MOTRIN) and naproxen sodium (ALEVE) all for an unknown indications on an unknown dates and experienced drug allergy. On 05Apr2021 at 15:00, the patient experienced very bad random itching without rash, like someone was poking randomly around her body (eye lid, scalp, thigh, arm, etc), with a pin, while it did not hurt but was itchy, the patient constantly wanted to scratch those different places. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of adverse event which included treatment with ALLEGRA. The clinical outcome of the event very bad random itching was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Chills, Dizziness, Pain, Pain in extremity
Clinical narrative: Chills; Fever; Sore arm; Weakness; Dizziness; Body aches; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 17Apr2021 at 09:30 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021 at 23:45, the patient experienced chills, fever, sore arm, weakness, dizziness and body aches. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 01Feb2021, the patient underwent Nasal Swab and the result was negative. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, sore arm, weakness, dizziness and body aches was recovered on an unknown date in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test
Clinical narrative: Chills; Fever; Sore arm; Weakness; Dizziness; Body aches; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 17Apr2021 at 09:30 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021 at 23:45, the patient experienced chills, fever, sore arm, weakness, dizziness and body aches. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 01Feb2021, the patient underwent Nasal Swab and the result was negative. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, sore arm, weakness, dizziness and body aches was recovered on an unknown date in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Head pain on left side encompassing cheekbone and reaching all the way back behind left ear and up to crown of head. Head pain has gotten worse over the last 24 hours.; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Apr2021 at 14:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cefalexin (CEPHALEXIN) and sulfamethoxazole, trimethoprim (BACTRIM) taken for an unknown indication, from an unknown date and unknown if ongoing. On 17Apr2021 at 15:30, the patient experienced head pain on left side encompassing cheekbone and reaching all the way back behind left ear and up to crown of head. Head pain had gotten worse over the last 24 hours. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event head pain on left side encompassing cheekbone and reaching all the way back behind left ear and up to crown of head was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: Menstrual cycle 15 days later; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the right arm on 14Apr2021 at 12:30 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medication within two weeks of vaccination. The patient's menstrual cycle started on 04Apr2021, her cycle was regular for every 24 to 28 days. On 19Apr2021 at 10:00, the patient got her menstrual cycle 15 days later, that was not normal. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event menstrual cycle 15 days later was unknown at the time of this report.   No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Rash morbilliform
Clinical narrative: Measles like rash on face the morning after both doses; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 28Mar2021 (at the age of 28-years-old) as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 18Apr2021 at 12:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 08:00, the patient experienced measles like rash on face the morning after both doses. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event measles like rash on face was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swelling lymph node in one of  breasts with the size as Lima bean; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date, the patient experienced swelling lymph node in one of the breasts with the size as lima bean. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swelling lymph node in one of the breasts with the size as lima bean was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Rash papular
Clinical narrative: Small red bumpy rash on mid on back; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08Apr2021 at 10:30 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 12Apr2021 at 13:00, the patient experienced small red bumpy rash on mid on back. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event small red bumpy rash on mid on back was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Dizziness, Lung disorder, Migraine
Clinical narrative: fever of 103; chills; lung discomfort; shooting pain down nerves; migraine; nausea; dizziness; soreness; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 20Apr2021 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 the patient experienced fever of 103 (unspecified unit), chills, shooting pain down nerves, lung discomfort, migraine, soreness, nausea and dizziness. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. On 20Apr2021 the patient checked her body temperature and it was 103(unspecified units). Therapeutic measures were not taken as a result of reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever of 103(unspecified units), chills, shooting pain down nerves, lung discomfort, migraine, soreness, nausea and dizziness were recovered with sequelae on an unknown date in Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia
Clinical narrative: fever of 103; chills; lung discomfort; shooting pain down nerves; migraine; nausea; dizziness; soreness; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 20Apr2021 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 the patient experienced fever of 103 (unspecified unit), chills, shooting pain down nerves, lung discomfort, migraine, soreness, nausea and dizziness. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. On 20Apr2021 the patient checked her body temperature and it was 103(unspecified units). Therapeutic measures were not taken as a result of reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever of 103(unspecified units), chills, shooting pain down nerves, lung discomfort, migraine, soreness, nausea and dizziness were recovered with sequelae on an unknown date in Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Periorbital swelling, Pruritus, Rash macular
Clinical narrative: shortness of breath; Itching; swelling under the eyes; red blotchy skin; This is a spontaneous report from a contactable consumer (patient). A 66-year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number: EN6203, expiration date was not reported), via an unspecified route of administration, administered in left arm on 04Mar2021 07:15 (at the age of 66-years-old) as dose 1, single for covid-19 immunization. The patient medical history included allergy to sulfa drugs, food allergy to chocolate. Concomitant medications were not reported. No other vaccine received in four weeks. No other medications received in two weeks. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. It was reported that, on 06Mar2021: 06:00 AM the patient experienced Itching, swelling under the eyes, red blotchy skin, shortness of breath. These are the same side effects when I take sulfa drugs. Patient took benadryl and used cortisone cream as treatment for adverse event. Therapeutic measures were taken as a result of shortness of breath, itching, swelling under the eyes, red blotchy skin. The outcome of the events was recovering.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Rash erythematous, Visual impairment
Clinical narrative: I was getting head ache with one side most of the time left side.; On my left leg 1 inch red and pinkish rash came with out pain.; Feeling like my eyes power changed. I was not able to see like before vaccination; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14Apr2021 at 18:30 (at the age of 38-year-old) as a single dose for COVID-19 immunisation.  Medical history was reported as unknown. It was unknown whether the patient was pregnant at the time of vaccination. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. It was unknown whether the patient had allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021, five days after the vaccination the patient experienced head ache with one side most of the time left side. The patient developed one inch red and pinkish rash on the left leg came without pain. Felt like eyes power changed. The patient was not able to see like before vaccination. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, one inch red and pinkish rash on the left leg, felt like eyes power changed, was not able to see like before vaccination were unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral, Paraesthesia, Paraesthesia oral
Clinical narrative: Numbness and tingling on left side of lips and left cheek; Numbness and tingling on left side of lips and left cheek; Numbness and tingling on left side of lips and left cheek; Numbness and tingling on left side of lips and left cheek; This is a spontaneous report from a contactable nurse, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 23:30 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included epstein-barr, melanoma and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received ciprofloxacin (CIPRO) on an unknown date for unknown indication and experienced drug allergy.  On an unknown date in 2021, the patient experienced numbness and tingling on left side of lips and left cheek which lasted for 10 minutes. The events resulted in emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events numbness and tingling on left side of lips and left cheek were resolved on an unknown date in 2021, after the duration of 10 minutes.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Injection site area larger; injection site itching; Large red raised area around injection site; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the right arm on 21Apr2021 at 09:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfa allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Patient received other vaccine within four weeks prior to the COVID vaccine. Patient received varicella zoster vaccine rgE (CHO) (SHINGRIX) on 09Mar2021. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the right arm on 24Mar2021 at 12:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 07:00, the patient experienced large red raised area around injection site, appeared two days after shot and on day 3, 23Apr2021, area was larger and itchy. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event large red raised area around injection site, appeared two days after shot and on day 3, 23Apr2021, area was larger and itchy was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Rash erythematous, Vaccination site erythema, Vaccination site swelling
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 20Apr2021 at 12:45 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis (MS), immunocompromised, type 2 diabetes mellitus, gastroparesis and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient received unspecified concomitant medications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 23Mar2021 at 13:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient previously took ciprofloxacin (CIPRO) for an unknown indication on an unknown date and experienced drug allergy. On 21Apr2021 at 04:00, the patient experienced a very sore arm. On 22Apr2021, two days later, the patient was covered in a hot, red rash on body, whole stomach and chest, arms, legs, back, buttocks. The vaccine site was red and swollen to the size of a softball. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events a very sore arm, covered in a hot, red rash on body, whole stomach and chest, arms, legs, back, buttocks, vaccine site was red and swollen to the size of a softball was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Headache, Malaise, Nausea, Pain
Clinical narrative: Fever 102.6; Nausea; Vomiting; Body aches; Headache; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0170) via an unspecified route of administration in the right arm on 21Apr2021 at 14:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other unspecified vaccine within four weeks prior to the vaccination on 01Apr2021. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 31Mar2021 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 04:30, the patient experienced fever 102.6, nausea, vomiting, body aches, headache and feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever 102.6, nausea, vomiting, body aches, headache and feeling unwell were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Fever 102.6; Nausea; Vomiting; Body aches; Headache; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0170) via an unspecified route of administration in the right arm on 21Apr2021 at 14:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other unspecified vaccine within four weeks prior to the vaccination on 01Apr2021. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the right arm on 31Mar2021 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 04:30, the patient experienced fever 102.6, nausea, vomiting, body aches, headache and feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever 102.6, nausea, vomiting, body aches, headache and feeling unwell were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Cold sweat, Nasopharyngitis, Pyrexia
Clinical narrative: Cold.; Clammy; Feeling like fever/ but no measurable fever; This is a spontaneous report from a contactable consumer, the parent. A 24-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had known allergy to lots of foods. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included allergy shots (as reported) for unknown indication from an unknown start date and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 22Apr2021, after 21 hours of vaccination, the patient experienced cold, clammy and feeling like fever, but no measurable fever. The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not  taken as a result events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events cold, clammy and feeling like fever but no measurable fever was unknown at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pain, Pain in extremity, Sensitive skin
Clinical narrative: Headache; achy upper body; sore upper legs; my skin was especially sensitive.; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 21Apr2021 at 13:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 31Mar2021 at 13:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021, at 07:00 the patient experienced headache, achy upper body, sore upper legs. The patient experienced upper body all felt sore and his skin was especially sensitive. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event headache, achy upper body, sore upper legs and skin sensitive were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.